OPTIGENTIN

Main information

  • Trade name:
  • OPTIGENTIN ANTIBIOTIC, OPHTHALMIC GEL
  • Pharmaceutical form:
  • MISC. AURAL, OPHTHALMIC, ORO/NASO PHARYNGEAL
  • Units in package:
  • 5mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • OPTIGENTIN ANTIBIOTIC, OPHTHALMIC GEL
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | DOG | HORSE | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH
  • Therapeutic area:
  • antibiotic
  • Therapeutic indications:
  • INFECTION - OCULAR | EYE INFECTIONS | OCULAR INFECTIONS
  • Product summary:
  • For the treatment of bacterial infections of the eye, susceptible to gentamicin in the dog, cat and horse.Not for use in food producing animals. Use restricted to situations where sensitivity indicates no other alternative antibiotic

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 36184/1004
  • Authorization date:
  • 10-02-2005
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Antibiotic

Ophthalmic

Optigentin

Fortile

l11almenl

bacte~

.ctIons

IlIe

eye,

suscepUb

genlamlcln, Intile

dog,

la nd

hom .

m<l'rrL

MIICl

SULF

Itlluiv.l!enl

3rr!i''rr.L

AMIC

'UiClIPIln

UIMl1I01EJI

ARST

I l l '

WClII

ClIIIIII

If poisoning

occur

AIIIIIII

IIUI1IEKI

I a d

OClor

or Poisons

Infor

mation

ntre.

Phone

Austra

l;;'

131126

Jurox

iners

Road

"

RUlherlo

2320,

AUSTRAl

Infollne:

1800023312

APVMA

3618415rnUlOO4

Siore below

25'C

(Air

d~ion

tect

fromlight.

ispose

empty c

onta

iner

wrap

ping

paper

andpl

acing

In ga

rbage

-

urox

base

balch

Xl)iI'(

'*"

...k

::::"...,

§ l

<1

t:

"

"';"'('

r

10

,,-,

,~(;

dl"'

' } d

IllRa:11ONS

fOIl

R8:itra

EIn food

produc

inganimals.

Userestricted

slluall ons

where senslll vity Indlcales

no olller alternalive

anllbiotle.

SSio

viral

o.lgin should be

apparent

prior

mrnet1clO

Optigentin ther

11'10

1I1e

should beinstilled inlo lhe

conj

unC1

threeor lour

esdOlll

MEAT

ITHHO

LDING

T TOBEUSED

oduc

ingmeal

huma

n consumplion,

Fortile

almenl

ol lhe

eye,

nlamlc

lIle

dog,

caU nd

I\of$e,

Antibiotic

Ophthalm

Optigentin

~'ml

SUlfATl

"lornlem

103 "'!i'

AMIC

U IMl1IlU1IIU1

'RIQIPIItI

U IMI1Il1UI

READ

ENClOSED

IIAA.ET

IIlP

IFHAU

ClIlIIII

IlERlRE

USING

THIS

PRODUCT

~~--

--------

PRESCRIPTION

ANIMAL

REMEDY

K EEP OUT OF

REAC

H OF CH

RE N

FO R

ANIMAL

TR EATMENT ONLY

OPTIGENTIN

A NTIBIO

OPHT HAL MIC GEL.

COMPOSITIO N:

Each rnt.comams

511'09

gentamicin suuate (equIValent103

gentamICin

base)

in a non-irritant

bas e and IllCO,pOra l

1!'S

0 ,02 mgr mL p heny l

mercuric

nitr ate a s its preservanve .

PROPERTIes :

Gen lamicirl

is o ne o f

lhe aminoglycosioe eono

nature 01 its

irreversib le inhibi'ion

protein

synth&sis,

is bacter icidal

is eceve

amsl

Gra m-positive org ani sms

mos t

m-ne

ga tive - ba cilli ,

,ncluding s tr

ains

Pseuoom

OfIBS

feus

whiCh ma y be resrstaot

other

antib iotiCS.lts

wide

spectrum of

antihacterial

cover

makes

effectiv e topica l

treatment

In both pnmary

secondary

bacteri al

in fectio ns

orire

eye and surrounding tissu es .

specifically develo ped g el

base provide s a vetlil;le In

teri nary

ophl halmlC pre par alions.

com bines

IhI!

desi red s ta oll ity of

individ ual

compon

ents with la ck o f irritancy. and film-sp rea d

activ e ingredient s to

hlle

nll re co

rnll

surface ,

IND ICAT ION S:

OPTIG E

N is Indicated

the tre atm en t o f

bactena

tions

ey e.

susc ep tible to ge ntamicin in the

dog ,

hors

OIRECTIO NS FOR US E:

TRAINT

NOT FOR USE In

rodu

cin g a ni

mals

Us e r e s

c t ed to

u aUo ns w he re se ns itiv i

Ind ica tes

o t he r

lIltllrn

ennereue.

Rem iss io n

ca ses

v i ral

o rig i n sho u ld

ap p are

ommenci

ng OPT

IGENT

IN th e

rllpy

drops

the gel

shoul d be in stIlled mto

con junctIval

tnree

four

times

da ily.

meet

ecrc

' ndivldual

cases.

appeceucn

frequ eflCY Should

gradually be

reduced.

Ther apy should not

prema1urel y Withdrawn .

Product

unused

aher

compl

ete ,

sllou

orsca

roeo

MEAT WITHHOLDI NG PERIOD :

USEO tN HOR SES

PRODUCING MEAT FOR HUMAN CO NSUMPTION ,

FIRST A ID;

poisonIng oc

curs

. contact

a Doctor or

Persons

Intormation Centre

Phone

Australia

SPOS

E 0 '

ccra a mer by wrap ping w ll h

paper

and plaCing

,1'1

ga rbage ,

STORE

b elow 2S"C (AIr Cond'lIonlng)

PRO TECT trom light

PRES ENTATIO N:

SmL applicator bcrtte .

ot>

Juro x

LId RegIste red TrM e Mark

Ma<le in

AUStralia by '

,,-urox

P ty. LId ,

as Gardlners Road

Rutherford,

NSW 2320.

AU STRALIA

In lohn e·

1800 023 31 2

_0429'

f>V

~AApp'oy.

"

J6100

lH104

25-10-2018

Safety of zinc chelate of methionine sulfate for the target species

Safety of zinc chelate of methionine sulfate for the target species

Published on: Wed, 24 Oct 2018 00:00:00 +0200 Zinc chelate of methionine sulfate is intended to be used as a nutritional additive (functional group: compounds of trace elements). The additive is zinc chelated with methionine in a molar ratio 1:1. It is intended to supply zinc as a nutritional additive to all animal species/categories. In 2017, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efficacy of zinc chelate of methionine su...

Europe - EFSA - European Food Safety Authority Publications

2-7-2018

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling

Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.

FDA - U.S. Food and Drug Administration

11-1-2019


Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-12-2018

Ziagen (ViiV Healthcare BV)

Ziagen (ViiV Healthcare BV)

Ziagen (Active substance: abacavir sulfate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8685 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/252/T/104

Europe -DG Health and Food Safety

3-12-2018


Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Withdrawn application: Zydax, glucuronoxylan sulfate sodium, Date of withdrawal: 03/12/2018, Initial authorisation

Europe - EMA - European Medicines Agency

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type: , therapeutic area: , PIP number: P/0223/2018

Europe - EMA - European Medicines Agency

19-11-2018


Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use

Europe - EMA - European Medicines Agency

30-10-2018

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate) - Orphan designation - Commission Decision (2018)7273 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/18

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02

Europe -DG Health and Food Safety

14-5-2018

Girolan and its associated name Apralan

Girolan and its associated name Apralan

Girolan and its associated name Apralan (Active substance: Apramycin sulfate) - Community Referrals - Art 34 - Commission Decision (2018)2989 of Mon, 14 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/122

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (IQVIA RDS Ireland Limited)

EU/3/16/1714 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate) - Transfer of orphan designation - Commission Decision (2018)1823 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/16/T/01

Europe -DG Health and Food Safety